The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Defining high-risk myeloma: exciting updates and their implications
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, discusses recent developments in defining high-risk multiple myeloma (HRMM), noting that, after 20 years of research, there is now an agreed-upon definition of high-risk disease. This new consensus will improve clinical trial design and enhance patient outcomes by incorporating advanced diagnostic tools like whole genome sequencing (WGS). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
